ReviewNeuropsychiatric disease and treatment2018
Alzheimer's disease and blood-based biomarkers - potential contexts of use.
Review in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of potential blood biomarkers for early diagnosis of Alzheimer's disease through RNA sequencing analysis.Alzheimer's research & therapy · 2020Pooled it
- CLIC1 Protein Accumulates in Circulating Monocyte Membrane during Neurodegeneration.International journal of molecular sciences · 2020Trial
- Histone Deacetylase Inhibitor Combined with Rosiglitazone Improves Cognitive Function Via Microglial Polarization and Increased Mature/Pro-BDNF in Alzheimer's Disease.Advanced pharmaceutical bulletin · 2026Article
- Potential Neuroprotective Role of GLP-2 in Alzheimer's Disease: Clinical Observations, Mechanistic Insights, and Comparison with GLP-1.International journal of molecular sciences · 2026Article
- Feasibility and validity of using self-collected capillary blood using Tasso+ for measuring Alzheimer's Disease plasma-based biomarkers among underrepresented populations.medRxiv : the preprint server for health sciences · 2026Article
- Stage-Dependent Function of Astrocytes in Alzheimer's Disease: A Review.Neuroscience insights · 2026Review
- Stability and chaos analysis of neurological disorder of complex network with fractional order comparative study.Scientific reports · 2025Article
- Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-based derivatives as multitarget anti-Alzheimer agents.RSC medicinal chemistry · 2024Article
- Interventions to Foster Resilience in Family Caregivers of People with Alzheimer's Disease: A Scoping Review.International journal of environmental research and public health · 2024Article
- Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease.Cellular and molecular neurobiology · 2023Review
- Article
- Scalar on time-by-distribution regression and its application for modelling associations between daily-living physical activity and cognitive functions in Alzheimer's Disease.Scientific reports · 2022Article
- Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease.Heliyon · 2022Review
- Antioxidant and Anticholinesterase Properties of the Aqueous Extract ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Analysis of behavioral management for dental treatment in patients with dementia using the Korean National Health Insurance data.Journal of dental anesthesia and pain medicine · 2021Article
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.Journal of internal medicine · 2021Review
- Biomarkers and Precision Medicine in Alzheimer's Disease.Advances in experimental medicine and biology · 2021Article
- Classifying Non-Dementia and Alzheimer's Disease/Vascular Dementia Patients Using Kinematic, Time-Based, and Visuospatial Parameters: The Digital Clock Drawing Test.Journal of Alzheimer's disease : JAD · 2021Article
- Predicting Dementia With Prefrontal Electroencephalography and Event-Related Potential.Frontiers in aging neuroscience · 2021Article
- Continuous gait monitoring discriminates community-dwelling mild Alzheimer's disease from cognitively normal controls.Alzheimer's & dementia (New York, N. Y.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment, and be used to detect the efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid and neuroimaging are highly accurate, but barriers to clinical implementation exist. The focus on blood-based AD biomarkers has grown exponentially during the past few decades. An ideal diagnostic test for AD should be noninvasive and easily applicable. Clinical cost-effectiveness also needs to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.